Opinion
As psychedelic-assisted therapies near FDA approval, questions remain about cost, who’s paying, and how much it saves patients and insurers in the long run.
In an era where thought leaders are minted by social media metrics, some influencers may be one viral video away from being tomorrow’s psychedelic luminaries.
The results of the company’s Phase 2b trial raise concerns around safety, efficacy, and money, suggesting key questions to be addressed in Phase 3.
UNIFY founder Adil Kassam discusses how technology coupled with global group meditation can facilitate synchronized transformational experiences among millions of people.
The medicalization of psychedelics may be changing people’s minds, but can these developments result in deeper changes in how we view or access medicine?
Psychedelic medicines make headlines for indications like PTSD, depression, and anxiety, but they’re being studied for a much broader range of conditions.
Game designer Robin Arnott discusses how psychedelics and virtual reality might collide, the potential risks of “digital psychedelics,” and how to Trojan Horse transformational experiences into virtual worlds.
Between tripping hard on 200 mcgs of acid and microdosing lies a vast dosing territory ripe for exploration and flow states.
After being diagnosed with cancer two days before his wedding, Steven Allgood turned to psilocybin to alleviate his end-of-life anxiety, and transform his perspective on life and what may come after.
The way patents in the psychedelic field can pose a problem is often misunderstood, mischaracterized, and sensationalized by the media and academics alike.
